This inventor holds 5 USPTO granted patents and 8 published patent applications and 3 EPO patents. Top assignees: Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts, Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft. Active years: 2015-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 168 
1 out of 12,268 
1 out of 387 
Years Active: 2015-2025
Title: **Jörg Willuda: A Pioneer in Antibody Research**
Introduction
Jörg Willuda is a noteworthy inventor based in Glienicke/Nordbahn, Germany, recognized for his innovations in the field of biopharmaceuticals. With a solid portfolio comprising five patents, his work primarily focuses on the development of antibody therapies aimed at treating various cancers and disorders.
Latest Patents
Among his latest contributions to the realm of medicine, one significant patent involves a pharmaceutical combination of anti-CEACAM6 and TIM3 antibodies. This innovative disclosure discusses combinations of component A, the anti-CEACAM6 antibody TPP-3310, and component B, an anti-TIM-3 antibody such as cobolimab, MBG-453, BMS-986258, Sym-023, LY-3321367, or INCAGN-2390. Another significant patent pertains to anti-CEACAM6 antibodies and their uses, which details recombinant antigen-binding regions and methods to generate antibodies specific to human CEACAM6, while avoiding cross-reactivity with similar human proteins. These antibodies hold potential for treating cancer and various conditions linked with the expression of CEACAM6, alongside providing nucleic acid sequences, vectors, and pharmaceutical compositions.
Career Highlights
Throughout his career, Jörg Willuda has collaborated with eminent organizations, notably the Deutsches Krebsforschungszentrum (German Cancer Research Center) and Seattle Genetics, Inc. His inventive contributions have made substantial impacts on the development of therapeutic antibodies and shed light on novel treatment methodologies.
Collaborations
Willuda's work has been significantly enhanced through collaborations with esteemed professionals such as Sven Golfier and Uwe Gritzan. These partnerships have allowed for the fusion of diverse expertise, further pushing the boundaries of research in biopharmaceutical applications.
Conclusion
In summary, Jörg Willuda exemplifies a remarkable inventor whose work continues to influence the medical research landscape. His patents showcase innovative approaches to antibody therapies, providing valuable tools in the fight against cancer and related disorders. As the field of biopharmaceuticals evolves, Willuda's contributions will likely remain at the forefront of therapeutic advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile